Bios Health Group Enters Life Sciences Market
Bios Health Group has entered the life sciences market. This new company entity is a strategic partner providing solutions for life science companies and investors. It offers strategies to attract funding, optimize clinical development, and create effective commercial strategies. Bios Health Group also serves as a venture partner providing investor preparation for Bbotech companies seeking investment funding and access to venture funds through its investor networks.
Bios Health Group Chief Executive Officer, Zizi Uzezi Imatorbhebhe, MBA MS PMP® said in a press release, "We are thrilled to bring this comprehensive suite of end-to-end solutions to biotech and life science companies. Our strategic approach involves engagement with venture capitalists and investors, effectively addressing the funding gap that often impedes early-stage biotech companies from accessing critical financial resources required to realize their innovative concepts. Additionally, we provide established companies with proven commercial strategies to launch new products and expand their market presence."
Bios Health Group offers four strategic solutions:
- BioInvest offers life science companies guidance on investment preparation including business plans, investor attractive investment pitches, and access to investor networks.
- Innovate Bio focuses on clinical development optimization, prioritizing R&D indications and pipelines to maximize value, leveraging innovations, strategic and patient-centric approaches to optimize and accelerate clinical development.
- CRO Select helps Biotech companies select the right fit CRO.
- LaunchMax offers commercial strategy development and execution. In addition, the BIOS Innovation Circle brings together strategic experts to provide tailored solutions.
Reference
Bios Health Group Enters the Market to Offer Investment-Driven and Clinical Development Optimization Strategies for Biotech and Life Science Companies. (2023, August 15). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
